This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. ACHC, BLTE, MESO, PGNY, ANIP, CGON, ADPT, ARQT, ATRC, and QDELShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Acadia Healthcare (ACHC), Belite Bio (BLTE), Mesoblast (MESO), Progyny (PGNY), ANI Pharmaceuticals (ANIP), CG Oncology (CGON), Adaptive Biotechnologies (ADPT), Arcutis Biotherapeutics (ARQT), AtriCure (ATRC), and QuidelOrtho (QDEL). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Its Competitors Acadia Healthcare Belite Bio Mesoblast Progyny ANI Pharmaceuticals CG Oncology Adaptive Biotechnologies Arcutis Biotherapeutics AtriCure QuidelOrtho Acadia Healthcare (NASDAQ:ACHC) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk. Which has preferable valuation & earnings, ACHC or LCAP? Acadia Healthcare has higher revenue and earnings than Lionheart Acquisition Co. II. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcadia Healthcare$3.15B0.67$255.61M$1.5115.21Lionheart Acquisition Co. IIN/AN/A$3.21MN/AN/A Do analysts rate ACHC or LCAP? Acadia Healthcare presently has a consensus price target of $40.77, suggesting a potential upside of 77.58%. Given Acadia Healthcare's stronger consensus rating and higher probable upside, equities research analysts plainly believe Acadia Healthcare is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acadia Healthcare 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ACHC or LCAP more profitable? Acadia Healthcare has a net margin of 4.31% compared to Lionheart Acquisition Co. II's net margin of 0.00%. Acadia Healthcare's return on equity of 8.34% beat Lionheart Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Acadia Healthcare4.31% 8.34% 4.20% Lionheart Acquisition Co. II N/A -44.30%1.39% Does the media prefer ACHC or LCAP? In the previous week, Acadia Healthcare had 9 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 9 mentions for Acadia Healthcare and 0 mentions for Lionheart Acquisition Co. II. Acadia Healthcare's average media sentiment score of 0.33 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Acadia Healthcare is being referred to more favorably in the media. Company Overall Sentiment Acadia Healthcare Neutral Lionheart Acquisition Co. II Neutral Which has more risk and volatility, ACHC or LCAP? Acadia Healthcare has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Lionheart Acquisition Co. II has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. SummaryAcadia Healthcare beats Lionheart Acquisition Co. II on 11 of the 11 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$517.83M$149.19M$5.76B$9.75BDividend YieldN/AN/A3.95%4.02%P/E RatioN/A159.3031.4526.39Price / SalesN/A21.92431.57159.28Price / Cash20.6411.7037.7559.42Price / Book-9.853.3610.566.59Net Income$3.21M$1.30M$3.27B$265.83M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$28.06+0.5%N/A+10,668.7%$517.83MN/A0.003ACHCAcadia Healthcare4.6942 of 5 stars$21.55-2.8%$40.77+89.2%-71.4%$2.05B$3.15B14.2725,500Positive NewsBLTEBelite Bio2.9577 of 5 stars$65.13+2.4%$96.67+48.4%+32.0%$2.03BN/A-42.0210Positive NewsMESOMesoblast2.9665 of 5 stars$16.00+1.8%$18.00+12.5%+150.4%$2.01B$5.90M0.0080News CoverageGap DownPGNYProgyny2.7016 of 5 stars$22.64-2.2%$25.30+11.7%+6.7%$1.99B$1.17B38.37310Positive NewsAnalyst ForecastANIPANI Pharmaceuticals3.2411 of 5 stars$91.89+1.7%$84.75-7.8%+47.5%$1.96B$747.40M-119.34600Insider TradeCGONCG Oncology1.4237 of 5 stars$27.03+6.3%$54.30+100.9%-27.4%$1.94B$1.14M-15.2761Positive NewsADPTAdaptive Biotechnologies2.5007 of 5 stars$12.80+1.0%$12.38-3.3%+195.1%$1.93B$178.96M-15.61790News CoverageARQTArcutis Biotherapeutics2.4777 of 5 stars$15.83+0.9%$19.80+25.1%+44.9%$1.88B$196.54M-21.11150Positive NewsATRCAtriCure2.9298 of 5 stars$37.87+0.1%$50.89+34.4%+45.4%$1.88B$499.95M-49.181,300Positive NewsInsider TradeQDELQuidelOrtho4.2092 of 5 stars$27.92+1.0%$42.17+51.0%-36.1%$1.88B$2.74B-4.276,600 Related Companies and Tools Related Companies ACHC Alternatives BLTE Alternatives MESO Alternatives PGNY Alternatives ANIP Alternatives CGON Alternatives ADPT Alternatives ARQT Alternatives ATRC Alternatives QDEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access